WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
Open Access
- 1 January 2013
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 14 (1) , 261
Abstract
Adjuvant treatment decision-making based on conventional clinical/pathological and prognostic single molecular markers or genomic signatures is a therapeutic area in which over-/under-treatment are still key clinical problems even though substantial and continuous improvement of outcome has been achieved over the past decades. Response to therapy is currently not considered in the decision-making procedure.Keywords
This publication has 26 references indexed in Scilit:
- Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)Breast Cancer Research and Treatment, 2013
- Chemotherapy regimens in early breast cancer: major controversies and future outlookExpert Review of Anticancer Therapy, 2013
- HER2 Status by Standardized Immunohistochemistry and Silver-EnhancedIn SituHybridization in Korean Breast CancerJournal of Breast Cancer, 2012
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Breast Cancer Research and Treatment, 2011
- Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewBreast Cancer Research and Treatment, 2011
- Adjuvant chemotherapy in luminal breast cancersThe Breast, 2011
- Quality assessment of HER2 testing by monitoring of positivity ratesVirchows Archiv, 2011
- Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × DocetaxelBMC Cancer, 2011
- Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20Journal of Clinical Oncology, 2010
- Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast CancerJNCI: Journal of the National Cancer Institute, 2007